Credit Suisse Starts Galapagos NV (GLPG) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Nomura Securities Starts Galapagos NV (GLPG) at Buy
June 8, 2015 9:31 AM EDTNomura Securities initiates coverage on Galapagos NV (NASDAQ: GLPG) with a Buy rating and a price target of $73.00.
Analyst M. Ian Somaiya commented, "Our Buy rating is supported by the blockbuster opportunity for the companys lead oral JAK1 inhibitor, filgotinib, for the... More
Cowen Starts Galapagos NV (GLPG) at Outperform
June 8, 2015 6:41 AM EDTCowen initiates coverage on Galapagos NV (NASDAQ: GLPG) with a Outperform rating.
Analyst Phil Nadeau commented, "Galapagos has advanced a broad and deep pipeline into clinical development, with four candidates currently in clinical testing. Filgotinib has produced impressive results in Ph. IIb trials in... More
